In a French study (CUTALLO) reported in The Lancet, de Masson et al found that patients with advanced-stage cutaneous T-cell lymphomas who were able to undergo allogeneic hematopoietic stem cell transplantation (HSCT) had prolonged progression-free survival vs matched patients receiving investigator-selected non-HSCT therapy. In the HSCT group, 51 patients were 1:1 matched to patients in the non-HSCT group. Median progression-free survival was 9.0 months in the matched HSCT group vs 3.0 months in the matched non-HSCT group. The cumulative incidence of relapse at 1 year was 45.4% in the matched HSCT group vs 86.0% in the matched non-HSCT group. Median overall survival was not reached in the matched HSCT group compared with 26.9 months in the matched non-HSCT group.